FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The goal for the project is the identification and optimization of anti-viral compounds.
This robust growth has come despite the raging pandemic for most part of the quarter
Subscribe To Our Newsletter & Stay Updated
